MaxisIT Inc.’s Post

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki MD MPH and Sinan B. Sarac (MD, MSc, PhD) share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/g7grSAvF #PrecisionOncology #NovelInsights

Biotech and Pharma companies - How do we determine the most efficient regulatory path for a co-developed companion diagnostic (CDx) test ? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. In this New Medicines, Novel Insights Oncology report, my colleagues, regulatory experts Mwango Kashoki MD MPH and Sinan B. Sarac (MD, MSc, PhD) share how to minimize time and resources: https://lnkd.in/erfnHJT4 #PrecisionOncology #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki MD MPH and Sinan B. Sarac (MD, MSc, PhD) share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eFczxcwh #PrecisionOncology #ParexelBiotech #NovelInsights

Hopefully we could land the new initiative in China

When ADC Therapeutics realized that paper lab notebooks were holding them back, it was time to move to a cloud-based lab management solution. The clinical-stage oncology drug discovery and development company needed a solution to help manage the vast amounts of data and improve opportunities for collaboration and connectivity across ADCTs sites globally. 🌎 We interviewed ADCT scientist, Charlie Britten to find out what impact investing in Labguru's management solution has had on the company in terms of streamlining processes and increasing productivity and collaboration. You can learn more by clicking on the link below to read the full case study.👇 https://bit.ly/3PzNkQi #ELN #Labguru #Labmanagement

Discover the Future of Oncology with the latest #capgemini Invent report on Innovation Models for Digital Therapeutics (DTx)!   Leading pharma and medical devices companies are joining forces with digital health startups to revolutionize the world of healthcare. But it is vital these partnerships answer business questions that can stimulate Innovation Discovery.   In Advancing Outcomes Design, the first of our two-part report, we examined the context of DTx in oncology from the clinical perspective. In this second part, we delve deep into the evaluation criteria for those same DTx solutions.   Authors @Camille Madelon, @Geoff McCleary, and @Sameera Singh focus on the following key considerations:    ✅ Desirability   ✅ Feasibility  ✅ Viability   Don't miss out on this invaluable resource! Dive into the future of digital therapeutics and uncover the secrets to success in oncology.   🔗 Download and read our new report: Digital Therapeutics in Oncology: Innovation Models https://bit.ly/41QVl88   Is your organization exploring the potential of digital therapeutics? 🤔 Let us know below! 👇   #digitalhealth #InnovationInOncology #futureofhealthcare #capgeminiinvent #getthefutureyouwant

𝐓𝐡𝐞 𝐅𝐃𝐀'𝐬 𝐠𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐩𝐢𝐥𝐨𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐭𝐡𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐭𝐞𝐬𝐭𝐢𝐧𝐠, 𝐚𝐧𝐝 𝐰𝐞'𝐯𝐞 𝐠𝐨𝐭 𝐭𝐡𝐞 𝐢𝐧𝐬𝐢𝐝𝐞 𝐬𝐜𝐨𝐨𝐩 𝐟𝐨𝐫 𝐲𝐨𝐮. 👇 In our latest article, Katy Barber dives deep into this game-changing initiative, speaking with Federico Goodsaid, SVP of Regulatory Affairs at Ariana Pharma, who brings nearly a decade of FDA experience to the table. This program is set to address long-standing regulatory challenges in in-vitro diagnostics and offers a solution that promises to revolutionise the industry. You can find out more about: 👉 Streamlined regulatory pathways for in vitro diagnostics 👉 Enhanced collaboration among labs 👉 Reduced R&D costs 👉 Potential for global adoption 👉 A brighter future for personalised medicine Discover how this program could pave the way for a more collaborative and efficient diagnostic landscape, not just in oncology but potentially in other fields such as neurology. Read the full article via the link in the comments, and stay tuned as we witness the unfolding of this transformative journey in healthcare. 👏 #Oncology #LifeScienceNews #FraserDove

📅Save the Date for the Fierce Biotech Summit 2024, where industry leaders discuss the evolving biotech landscape, including AI in drug development, dealmaking strategies, and oncology innovations. Join us on September 30 - October 1, 2024, in Boston, MA. Connect with seasoned executives and explore the future of biotech. Brought to you by the editors behind Fierce Biotech, this three-day event will cover the use of AI in drug development, unique dealmaking strategies, the latest innovations in oncology and much more. Interested in attending? Join our mailing list to stay updated on when registration will be open✅https://lnkd.in/dmcFa2Sa #FierceBiotechSummit #BiotechInnovation #SaveTheDate

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/etSKQC_F #PrecisionOncology #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/dFA4KCCg #PrecisionOncology #NovelInsights